Follistatin 315 vs Melanotan 1
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 315Skin & CosmeticSexual Health & Libido
Melanotan 1- Summary
- Follistatin 315 is a splice variant isoform of follistatin produced by alternative mRNA processing. Unlike Follistatin 344 which is tethered to cell surfaces via heparan sulfate proteoglycans, FST-315 circulates freely in the bloodstream and has broader systemic distribution. It is the predominant circulating form and exerts systemic myostatin inhibition as well as FSH suppression, making it relevant to both muscle growth and reproductive endocrinology.
- Melanotan 1 (Afamelanotide) is a synthetic analog of α-MSH that selectively stimulates melanogenesis (tanning) through MC1R activation. It provides UV-independent skin pigmentation and is FDA/EMA-approved under the name SCENESSE for erythropoietic protoporphyria (EPP) and vitiligo.
- Half-Life
- ~3–5 hours (longer systemic circulation vs FST-344)
- ~40–60 minutes (free peptide); implant formulation (SCENESSE) releases over months
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- No established human dosing protocol
- 0.5–1 mg
- Frequency
- Research use only
- Daily until desired color achieved, then maintenance
- Key Benefits
- Systemic myostatin inhibition for whole-body muscle growth
- Freely circulating — broader tissue distribution than FST-344
- Strong FSH-suppressive activity useful in certain hormonal protocols
- Potential for greater anabolic effect across multiple muscle groups simultaneously
- May be more relevant to reproductive endocrinology applications
- Studied in gene therapy approaches for muscular dystrophy
- Induces skin pigmentation/tanning without UV exposure
- Provides photoprotection in photosensitivity conditions (EPP)
- FDA-approved for erythropoietic protoporphyria (SCENESSE)
- Approved in EU for EPP treatment
- Anti-inflammatory via MC1R
- Mild libido enhancement
- Potential skin cancer prevention through melanin protection
- Side Effects
- Systemic FSH suppression — significant concern for fertility
- Greater potential for off-target effects vs FST-344 due to systemic distribution
- Limited human safety data
- Potential cardiac hypertrophy with prolonged high-dose exposure
- Nausea (especially at higher doses)
- Facial flushing
- Fatigue
- Injection site reactions
- +3 more
- Stacks With
- —
- —